Cedars-Sinai Medical Center
- Type
- Teaching hospital
- Where
- West Hollywood, CA
- Medicare CCN
- 050625
- Received
- $20,926,056 in 1,315 records, 2023 ($6,613,461 general, $14,312,595 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Cedars-Sinai Medical Center Fuzzy (name and state)
- Business registration: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Nonprofit contractor: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying registrant: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Patent assignee: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: Cedars-Sinai Medical Center Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 323 | $6,613,461 |
| 2023 | Research payment | 992 | $14,312,595 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 992 | $14,312,595 |
| Royalty or License | 19 | $4,352,619 |
| Grant | 88 | $1,465,855 |
| Space rental or facility fees (teaching hospital only) | 79 | $249,358 |
| Education | 62 | $221,387 |
| Long term medical supply or device loan | 23 | $125,636 |
| Debt forgiveness | 18 | $118,901 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 27 | $48,029 |
| Consulting Fee | 2 | $19,672 |
| Charitable Contribution | 5 | $12,000 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Merck Sharp & Dohme LLC | $391,414 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $301,597 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $285,504 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Pilot Study of Immune Checkpoint Inhibition with Pembrolizumab in Advanced BRCA-mutated Breast Cancers | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $205,590 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A SINGLE-CENTER OPEN-LABEL PROSPECTIVE PILOT STUDY OF POSACONAZOLE IN GENETICALLY-DEFINED PATIENTS WITH ACTIVE CROHN'S D | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $145,540 | Research payment | Cash or cash equivalent | Biological, CARDIOVASCULAR | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for | 2023 |
| 2023-12-31 | Siemens Medical Solutions USA, Inc. | $109,595 | Research payment | In-kind items and services | Eclipse Treatment Planning System for External Beam Radiation Therapy Device, Oncology | Cardiac RADIoablation versus repeat catheter Ablation: a pivotalrandomized clinical Trial Evaluating safety and efficacy | 2023 |
| 2023-12-31 | Stryker Corporation | $107,773 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Merck Sharp & Dohme LLC | $76,999 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $55,575 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase Ib,II Trial of anti-PD-1 immunotherapy and Stereotactic Radiation in Patients with Recurrent Glioblastoma | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $55,575 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Reinvigorating TNBC Response to Immunotherapy with Combination Myeloid Inhibition and Radiation | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $42,919 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $31,993 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $26,147 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $22,038 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2023 |
| 2023-12-31 | Intuitive Surgical, Inc. | $16,978 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $16,967 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Multicenter, Open-label Phase 2 Study of Lenvatinib E7080,MK-7902 Plus Pembrolizumab MK-3475 in Previously Treated Sub | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $16,150 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $13,831 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR | 2023 |
| 2023-12-31 | AngioDynamics, Inc. | $13,000 | Long term medical supply or device loan | In-kind items and services | Solero Device, Oncology | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $12,747 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with | 2023 |
| 2023-12-31 | KARL STORZ Endoscopy-America | $10,886 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $10,713 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $7,769 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $7,467 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy with or without Pembrolizumab MK-3475 in | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $6,222 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2023 |
| 2023-12-31 | Brahms GmbH | $6,000 | Research payment | In-kind items and services | BRAHMS KRYPTOR compact PLUS (instrument) Device, Kryptor instrument | First Trimester Risk Assessment for Preeclampsia study (FITRAPS) | 2023 |
| 2023-12-31 | Stryker Corporation | $5,135 | Long term medical supply or device loan | In-kind items and services | EZOUT Device, SURGICAL | 2023 | |
| 2023-12-31 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2023 | |
| 2023-12-31 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $4,828 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2023 |
| 2023-12-31 | KARL STORZ Endoscopy-America | $4,462 | Education | In-kind items and services | IMAGE 1 S Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $4,452 | Education | In-kind items and services | IMAGE 1 S Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | Stryker Corporation | $4,087 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Stryker Corporation | $4,045 | Long term medical supply or device loan | In-kind items and services | SYSTEM 7 STRYKER PRECISION Device, SURGICAL | 2023 | |
| 2023-12-31 | Stryker Corporation | $4,045 | Long term medical supply or device loan | In-kind items and services | SYSTEM 7 STRYKER PRECISION Device, SURGICAL | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $3,552 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB MK-3475, NSC #776864 IN ADDITION TO PACLITAXEL AND CAR | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $3,483 | Research payment | In-kind items and services | Biological, CARDIOVASCULAR | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for | 2023 |
| 2023-12-31 | KARL STORZ Endoscopy-America | $3,235 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $3,078 | Research payment | In-kind items and services | LAGEVRIO Biological, INFECTIOUS DISEASE | A Phase 2,3 Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokin | 2023 |
| 2023-12-31 | Intuitive Surgical, Inc. | $2,742 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2023 | |
| 2023-12-31 | Intuitive Surgical, Inc. | $2,742 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2023 | |
| 2023-12-31 | Stryker Corporation | $2,651 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $2,590 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy with or without Pembrolizumab MK-3475 in | 2023 |
| 2023-12-31 | KARL STORZ Endoscopy-America | $2,449 | Education | In-kind items and services | IMAGE 1 S Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $2,421 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2023 |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $2,292 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | To assess the efficacy and safety of AZD9291 versus Placebo in patients with Epidermal Growth Factor Receptor Mutation P | 2023 |
| 2023-12-31 | KARL STORZ Endoscopy-America | $2,289 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2023 | |
| 2023-12-31 | Stryker Corporation | $2,217 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $2,193 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2023 |
| 2023-12-31 | KARL STORZ Endoscopy-America | $2,164 | Education | In-kind items and services | IMAGE 1 S Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $2,079 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $1,373 | Education | In-kind items and services | 2023 | ||
| 2023-12-31 | Merck Sharp & Dohme LLC | $1,364 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $1,170 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose C | 2023 |
| 2023-12-31 | Stryker Corporation | $1,114 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | ABBVIE INC. | $1,056 | Research payment | In-kind items and services | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $1,029 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | 2023 |
| 2023-12-31 | KARL STORZ Endoscopy-America | $943 | Education | In-kind items and services | 2023 | ||
| 2023-12-31 | KARL STORZ Endoscopy-America | $860 | Education | In-kind items and services | 2023 | ||
| 2023-12-31 | Stryker Corporation | $741 | Long term medical supply or device loan | In-kind items and services | STRYKER Device, SURGICAL | 2023 | |
| 2023-12-31 | Medline Industries LP | $644 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | KARL STORZ Endoscopy-America | $643 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $469 | Education | In-kind items and services | IMAGE 1 S Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | ABBVIE INC. | $450 | Research payment | In-kind items and services | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumor | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $448 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $435 | Education | In-kind items and services | 2023 | ||
| 2023-12-31 | Merck Sharp & Dohme LLC | $435 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2023 |
| 2023-12-31 | KARL STORZ Endoscopy-America | $409 | Education | In-kind items and services | IMAGE 1 S Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $394 | Education | In-kind items and services | 2023 | ||
| 2023-12-31 | KARL STORZ Endoscopy-America | $394 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2023 | |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $392 | Research payment | In-kind items and services | A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progr | 2023 | |
| 2023-12-31 | ENCORE MEDICAL, LP | $321 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | KARL STORZ Endoscopy-America | $307 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $291 | Education | In-kind items and services | 2023 | ||
| 2023-12-31 | Edwards Lifesciences Corporation | $223 | Long term medical supply or device loan | In-kind items and services | HemoSphere Device, Hemodynamic Monitoring | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $218 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2023 | |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $213 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2023 |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $161 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | \";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in P | 2023 |
| 2023-12-31 | KARL STORZ Endoscopy-America | $122 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2023 | |
| 2023-12-31 | Medline Industries LP | $117 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | KARL STORZ Endoscopy-America | $96 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2023 | |
| 2023-12-31 | ABBVIE INC. | $88 | Research payment | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Inte | 2023 |
| 2023-12-31 | Medline Industries LP | $81 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | KARL STORZ Endoscopy-America | $55 | Education | In-kind items and services | 2023 | ||
| 2023-12-31 | KARL STORZ Endoscopy-America | $49 | Education | In-kind items and services | IMAGE 1 S Device, VIDEOIMAGING | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $47 | Education | In-kind items and services | 2023 | ||
| 2023-12-31 | Stryker Corporation | $43 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | KARL STORZ Endoscopy-America | $22 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2023 | |
| 2023-12-31 | Stryker Corporation | $13 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | KARL STORZ Endoscopy-America | $12 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $10 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $9 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2023 | |
| 2023-12-31 | KARL STORZ Endoscopy-America | $8 | Education | In-kind items and services | IMAGE 1 S Device, VIDEOIMAGING | 2023 | |
| 2023-12-28 | KARL STORZ Endoscopy-America | $4,733 | Education | In-kind items and services | 2023 | ||
| 2023-12-27 | Abbott Laboratories | $760 | Research payment | Cash or cash equivalent | JETI PERIPHERAL CATHETER Device, Vascular | JETi Peripheral Thrombectomy Registry (JETi) | 2023 |
| 2023-12-27 | KARL STORZ Endoscopy-America | $285 | Education | In-kind items and services | 2023 | ||
| 2023-12-27 | KARL STORZ Endoscopy-America | $23 | Education | In-kind items and services | 2023 | ||
| 2023-12-25 | AstraZeneca Pharmaceuticals LP | $2,750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ANDEXXA Biological, Rare Disease | 2023 | |
| 2023-12-25 | Ethicon Endo-Surgery Inc. | $400 | Research payment | Cash or cash equivalent | Echelon; Endopath Device, Endo-Mechanical | A Multi-Center Evaluation of the ECHELONT 3000 (Next Generation Powered Stapler) in Laparoscopic Sleeve Gastrectomy and | 2023 |
| 2023-12-25 | Ethicon Endo-Surgery Inc. | $390 | Research payment | Cash or cash equivalent | Echelon; Endopath Device, Endo-Mechanical | A Multi-Center Evaluation of the ECHELONT 3000 (Next Generation Powered Stapler) in Laparoscopic Sleeve Gastrectomy and | 2023 |
| 2023-12-25 | Ethicon Endo-Surgery Inc. | $250 | Research payment | Cash or cash equivalent | Echelon; Endopath Device, Endo-Mechanical | A Multi-Center Evaluation of the ECHELONT 3000 (Next Generation Powered Stapler) in Laparoscopic Sleeve Gastrectomy and | 2023 |
| 2023-12-22 | W. L. Gore & Associates, Inc. | $5,084 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE TAG Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch an | 2023 |
| 2023-12-22 | Biosense Webster, Inc. | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-12-22 | Janssen Research & Development, LLC | $831 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Co | 2023 | |
| 2023-12-22 | Biosense Webster, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-12-22 | Biosense Webster, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-12-21 | Edwards Lifesciences Corporation | $100,000 | Grant | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | 2023 | |
| 2023-12-21 | Veloxis Pharmaceuticals, Inc. | $23,554 | Research payment | Cash or cash equivalent | ENVARSUS Drug, TRANSPLANTATION | A PROSPECTIVE, PILOT TRIAL TO COMPARE THE EFFICACY OF TACROLIMUS EXTENDED-RELEASE (ENVARSUS XR) TO TACROLIMUS IMMEDIATE- | 2023 |
| 2023-12-21 | Blueprint Medicines Corporation | $9,092 | Research payment | Cash or cash equivalent | BLU-945-1101 | 2023 | |
| 2023-12-21 | Janssen Research & Development, LLC | $3,700 | Research payment | Cash or cash equivalent | An Open label Multi Center Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Deli | 2023 | |
| 2023-12-21 | Fisher Scientific Company L.L.C. | $12 | Research payment | In-kind items and services | sFlt-1 Device, prenatal screening | Identification and validation of a cut-off for the ratio of suluble Fms-like Tyrosine Kinase-1 to Placental Growth Facto | 2023 |
| 2023-12-20 | Merz Pharmaceuticals, LLC | $5,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-12-20 | Genmab A/S | $3,017 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-20 | Genmab A/S | $3,017 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-20 | Genmab A/S | $2,977 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-20 | Genmab A/S | $2,950 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-20 | Genmab A/S | $2,885 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-20 | Brahms GmbH | $2,505 | Research payment | In-kind items and services | BRAHMS sFlt-1 KRYPTOR kits, CAL and QC Device, prenatal screening | First Trimester Risk Assessment for Preeclampsia study (FITRAPS) | 2023 |
| 2023-12-20 | W. L. Gore & Associates, Inc. | $2,358 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE TAG Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch an | 2023 |
| 2023-12-20 | Genmab A/S | $2,031 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-20 | Genmab A/S | $1,790 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-20 | Genmab A/S | $1,725 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-20 | Genmab A/S | $1,725 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-20 | Grifols Biologicals LLC | $1,373 | Research payment | In-kind items and services | Albutein Biological, Critical Care Medicine | Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With Acute-On-Chroni | 2023 |
| 2023-12-20 | Genmab A/S | $442 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-20 | Genmab A/S | $442 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-12-18 | Ethicon Endo-Surgery Inc. | $20,046 | Research payment | Cash or cash equivalent | Echelon; Endopath Device, Endo-Mechanical | A Multi-Center Evaluation of the ECHELONT 3000 (Next Generation Powered Stapler) in Laparoscopic Sleeve Gastrectomy and | 2023 |
| 2023-12-18 | Boston Scientific Corporation | $15,119 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product IC | ACURATE IDE | 2023 |
| 2023-12-18 | Synthes GmbH | $10,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-12-18 | Boston Scientific Corporation | $7,033 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product PI | ELEGANCE | 2023 |
| 2023-12-18 | Medical Device Business Services, Inc. | $5,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-12-18 | PROGENICS PHARMACEUTICALS, INC. | $4,927 | Research payment | Cash or cash equivalent | PYLARIFY Drug, RADIOPHARMACEUTICAL | HIGH-RESOLUTION, 18F-PSMA PET-MRI FOR MAPPING PROSTATE CANCER IN PATIENTS CONSIDERING FOCAL HIGH-INTENSITY FOCUSED ULTRA | 2023 |
| 2023-12-18 | Boston Scientific Corporation | $1,560 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product PI | HI PEITHO | 2023 |
| 2023-12-18 | Janssen Research & Development, LLC | $623 | Research payment | Cash or cash equivalent | ERLEADA Drug, Oncology | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2023 |
| 2023-12-15 | Grifols Biologicals LLC | $2,747 | Research payment | In-kind items and services | Albutein Biological, Critical Care Medicine | Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With Acute-On-Chroni | 2023 |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $9,613 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $5,337 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $4,497 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | ABBVIE INC. | $4,405 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Inte | 2023 |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $1,974 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $1,705 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $1,413 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Medtronic, Inc. | $819 | Research payment | Cash or cash equivalent | INFUSE BONE GRAFT Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2023 |
| 2023-12-14 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2023 |
| 2023-12-14 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2023 |
| 2023-12-14 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2023 |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $100 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $100 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $100 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $100 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $100 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $87 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $87 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $87 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $79 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $79 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $79 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $58 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $58 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $33 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $31 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $31 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $31 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $31 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $24 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $24 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $24 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $24 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $18 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $18 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $18 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $18 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $17 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $17 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $15 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $15 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $15 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $15 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $10 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-14 | Regeneron Pharmaceuticals, Inc. | $10 | Research payment | Cash or cash equivalent | A Dose Escalation and Proof-of-Concept Study of REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) for Desensitizat | 2023 | |
| 2023-12-13 | Merck Sharp & Dohme LLC | $205,144 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2023 |
| 2023-12-13 | Merck Sharp & Dohme LLC | $179,451 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2023 |
| 2023-12-13 | SEAGEN INC. | $10,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $3,197 | Research payment | Cash or cash equivalent | RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL) | 2023 | |
| 2023-12-13 | Gilead Sciences, Inc. | $2,950 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-12-11 | GENZYME CORPORATION | $20,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-12-11 | Janssen Research & Development, LLC | $6,624 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2023 | |
| 2023-12-11 | GENZYME CORPORATION | $4,186 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With | 2023 |
| 2023-12-08 | Incyte Corporation | $2,660 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participan | 2023 | |
| 2023-12-07 | Alnylam Pharmaceuticals Inc. | $10,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-12-07 | ABBVIE INC. | $7,550 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Inte | 2023 |
| 2023-12-07 | PROGENICS PHARMACEUTICALS, INC. | $4,927 | Research payment | Cash or cash equivalent | PYLARIFY Drug, RADIOPHARMACEUTICAL | HIGH-RESOLUTION, 18F-PSMA PET-MRI FOR MAPPING PROSTATE CANCER IN PATIENTS CONSIDERING FOCAL HIGH-INTENSITY FOCUSED ULTRA | 2023 |
| 2023-12-07 | Premia Spine, Ltd. | $2,398 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2023 |
| 2023-12-06 | Alnylam Pharmaceuticals Inc. | $15,764 | Research payment | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety | 2023 |
| 2023-12-06 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-12-06 | ABBVIE INC. | $1,950 | Research payment | Cash or cash equivalent | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and or Refractory Solid Tumor | 2023 | |
| 2023-12-05 | ABBVIE INC. | $2,275 | Research payment | Cash or cash equivalent | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and or Refractory Solid Tumor | 2023 | |
| 2023-12-05 | ABBVIE INC. | $2,275 | Research payment | Cash or cash equivalent | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and or Refractory Solid Tumor | 2023 | |
| 2023-12-05 | Travere Therapeutics, Inc. | $1,950 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2023 | |
| 2023-12-05 | Travere Therapeutics, Inc. | $1,690 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2023 |
The latest 200 records of 1,315.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In West Hollywood, CA, county Los Angeles County, CA, state California; placed by its city name.
| Measure | Place (city or town) West Hollywood, CA | County Los Angeles County, CA | State California |
|---|---|---|---|
| Population B01003 | 34,884 | 9,808,667 | 39,287,377 |
| Population, 2020 census P1 | 35,757 | 10,014,009 | 39,538,223 |
| Median age B01002 | 40.0 | 38.2 | 37.9 |
| Under 18 B01001 | 3.6% | 20.6% | 22.0% |
| 65 and over B01001 | 16.8% | 15.2% | 15.7% |
| Households B11001 | 22,920 | 3,416,449 | 13,548,091 |
| Foreign born B05002 | 23.6% | 33.4% | 27.0% |
| Median household income B19013 | $96,995 | $90,112 | $99,122 |
| Median family income B19113 | $126,364 | $101,573 | $113,346 |
| Per capita income B19301 | $90,080 | $45,792 | $49,513 |
| Poverty rate B17001 | 12.9% | 13.7% | 12.0% |
| Unemployment rate B23025 | 8.9% | 7.3% | 6.6% |
| Civilian labor force B23025 | 25,818 | 5,200,656 | 20,068,466 |
| Mean commute (minutes) B08013 | 27.1 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 64.2% | 36.0% | 37.1% |
| Housing units B25001 | 26,079 | 3,650,466 | 14,644,735 |
| Owner-occupied B25003 | 19.8% | 45.9% | 55.9% |
| Renters B25003 | 80.2% | 54.1% | 44.1% |
| Median home value B25077 | $924,800 | $834,200 | $734,700 |
| Median gross rent B25064 | $2,091 | $1,954 | $2,036 |
| White, not Hispanic B03002 | 69.5% | 24.7% | 33.8% |
| Black B03002 | 4.3% | 7.4% | 5.2% |
| Hispanic or Latino B03002 | 13.1% | 48.4% | 40.2% |
| Asian B03002 | 6.1% | 14.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in West Hollywood, CA.
Comments